• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清 BAFF 在 IgA 肾病患者中升高,并与临床和组织病理学特征相关。

Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features.

机构信息

Department of Microbiology and Immunology, Key Immunopathology Laboratory of Guangdong Province, Shantou University Medical College, Shantou, Guangdong, PR China.

出版信息

J Nephrol. 2013 Jul-Aug;26(4):683-90. doi: 10.5301/jn.5000218. Epub 2012 Oct 4.

DOI:10.5301/jn.5000218
PMID:23042433
Abstract

BACKGROUND

B-cell-activating factor belonging to the tumor necrosis factor family (BAFF) has been found to have the function of activating B cells and participating in the class switching of B cells; however, its clinical application needs further study. In the present study, the serum BAFF levels of patients with IgA nephropathy (IgAN) with different histopathological phenotypes were measured.

METHODS

Levels of serum BAFF in 153 patients with IgAN, 55 healthy controls and 20 disease controls were recorded using commercially available ELISA kits. Their correlations with clinical and histopathological features of patients with IgAN were further evaluated.

RESULTS

Levels of serum BAFF in patients with IgAN were significantly higher than in controls. Serum BAFF levels were significantly higher in patients with mesangial hypercellularity and segmental glomerulosclerosis than in those without. Serum BAFF levels were associated with the severity of tubular atrophy/interstitial fibrosis. Serum BAFF levels were significantly positively correlated with estimated glomerular filtration rate and serum creatinine. Patients with elevated serum BAFF levels showed significantly greater severity in clinical and histopathological stages.

CONCLUSION

Levels of serum BAFF were elevated in patients with IgAN and were associated with clinical and pathological features of the disease. Serum BAFF levels could be a noninvasive biomarker for monitoring disease severity of IgAN.

摘要

背景

B 细胞激活因子属于肿瘤坏死因子家族(BAFF),已被发现具有激活 B 细胞和参与 B 细胞类别转换的功能;然而,其临床应用需要进一步研究。在本研究中,测量了不同组织病理学表型的 IgA 肾病(IgAN)患者的血清 BAFF 水平。

方法

使用市售 ELISA 试剂盒记录 153 例 IgAN 患者、55 名健康对照者和 20 名疾病对照者的血清 BAFF 水平,并进一步评估其与 IgAN 患者临床和组织病理学特征的相关性。

结果

IgAN 患者的血清 BAFF 水平明显高于对照组。系膜细胞增生和节段性肾小球硬化患者的血清 BAFF 水平明显高于无系膜细胞增生和节段性肾小球硬化患者。血清 BAFF 水平与肾小管萎缩/间质纤维化的严重程度相关。血清 BAFF 水平与估计肾小球滤过率和血清肌酐呈显著正相关。血清 BAFF 水平升高的患者在临床和组织病理学分期中表现出更严重的病情。

结论

IgAN 患者的血清 BAFF 水平升高,并与疾病的临床和病理特征相关。血清 BAFF 水平可能是监测 IgAN 疾病严重程度的非侵入性生物标志物。

相似文献

1
Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features.血清 BAFF 在 IgA 肾病患者中升高,并与临床和组织病理学特征相关。
J Nephrol. 2013 Jul-Aug;26(4):683-90. doi: 10.5301/jn.5000218. Epub 2012 Oct 4.
2
Expression profile of BAFF in peripheral blood from patients of IgA nephropathy: Correlation with clinical features and Streptococcus pyogenes infection.IgA肾病患者外周血中BAFF的表达谱:与临床特征及化脓性链球菌感染的相关性
Mol Med Rep. 2017 Apr;15(4):1925-1935. doi: 10.3892/mmr.2017.6190. Epub 2017 Feb 10.
3
TLR9 and BAFF: their expression in patients with IgA nephropathy.Toll样受体9(TLR9)与B细胞活化因子(BAFF):它们在IgA肾病患者中的表达
Mol Med Rep. 2014 Sep;10(3):1469-74. doi: 10.3892/mmr.2014.2359. Epub 2014 Jul 1.
4
[Therapeutic effects and prognostic factors in tonsillectomy patients with IgA nephropathy].[IgA肾病扁桃体切除患者的治疗效果及预后因素]
Nihon Jibiinkoka Gakkai Kaiho. 2007 Feb;110(2):53-9. doi: 10.3950/jibiinkoka.110.53.
5
Increase in B-cell-activation factor (BAFF) and IFN-gamma productions by tonsillar mononuclear cells stimulated with deoxycytidyl-deoxyguanosine oligodeoxynucleotides (CpG-ODN) in patients with IgA nephropathy.IgA肾病患者中,脱氧胞苷-脱氧鸟苷寡脱氧核苷酸(CpG-ODN)刺激扁桃体单个核细胞后,B细胞激活因子(BAFF)和干扰素-γ产生增加。
Clin Immunol. 2008 Mar;126(3):260-9. doi: 10.1016/j.clim.2007.11.003. Epub 2008 Jan 14.
6
Serum BAFF and APRIL might be associated with disease activity and kidney damage in patients with anti-glomerular basement membrane disease.血清 BAFF 和 APRIL 可能与抗肾小球基底膜病患者的疾病活动和肾脏损伤有关。
Nephrology (Carlton). 2013 Mar;18(3):209-14. doi: 10.1111/nep.12032.
7
Serum levels of tumor necrosis factor alpha in patients with IgA nephropathy are closely associated with disease severity.IgA 肾病患者的肿瘤坏死因子-α 血清水平与疾病严重程度密切相关。
BMC Nephrol. 2018 Nov 14;19(1):326. doi: 10.1186/s12882-018-1069-0.
8
Synthetic Double-Stranded RNA Poly(I:C) Aggravates IgA Nephropathy by Triggering IgA Class Switching Recombination through the TLR3-BAFF Axis.合成双链RNA聚肌苷酸胞嘧啶核苷(Poly(I:C))通过TLR3-BAFF轴触发IgA类别转换重组加重IgA肾病。
Am J Nephrol. 2015;42(3):185-97. doi: 10.1159/000440819. Epub 2015 Sep 30.
9
Insulin-like growth factor binding protein-1 levels are increased in patients with IgA nephropathy.胰岛素样生长因子结合蛋白-1 水平在 IgA 肾病患者中升高。
Biochem Biophys Res Commun. 2010 Aug 20;399(2):144-9. doi: 10.1016/j.bbrc.2010.07.032. Epub 2010 Jul 15.
10
BAFF is involved in the pathogenesis of IgA nephropathy by activating the TRAF6/NF‑κB signaling pathway in glomerular mesangial cells.BAFF 通过激活肾小球系膜细胞中的 TRAF6/NF-κB 信号通路参与 IgA 肾病的发病机制。
Mol Med Rep. 2020 Feb;21(2):795-805. doi: 10.3892/mmr.2019.10870. Epub 2019 Dec 6.

引用本文的文献

1
BAFF/APRIL expression-guided telitacicept therapy demonstrates superior efficacy in systemic lupus erythematosus patients: a real-world comparative study.BAFF/APRIL表达引导的泰它西普治疗在系统性红斑狼疮患者中显示出卓越疗效:一项真实世界比较研究
Front Med (Lausanne). 2025 Aug 22;12:1608085. doi: 10.3389/fmed.2025.1608085. eCollection 2025.
2
Exploring the role of APRIL in autoimmunity: implications for therapeutic targeting in systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome.探索增殖诱导配体(APRIL)在自身免疫中的作用:对系统性红斑狼疮、类风湿关节炎和干燥综合征治疗靶点的启示
Front Immunol. 2025 Aug 1;16:1523392. doi: 10.3389/fimmu.2025.1523392. eCollection 2025.
3
Opportunities and challenges in the treatment of IgA nephropathy.
IgA肾病治疗中的机遇与挑战。
Front Pharmacol. 2025 Jul 30;16:1559593. doi: 10.3389/fphar.2025.1559593. eCollection 2025.
4
Recent advances in pathogenetic concepts and disease modeling of IgA nephropathy.IgA肾病发病机制概念与疾病建模的最新进展
Clin Kidney J. 2025 May 16;18(6):sfaf152. doi: 10.1093/ckj/sfaf152. eCollection 2025 Jun.
5
Causal relationships between immune cell phenotypes and primary glomerular diseases: genetic evidence from bidirectional Mendelian randomization study.免疫细胞表型与原发性肾小球疾病之间的因果关系:双向孟德尔随机化研究的遗传学证据
Clin Kidney J. 2025 Feb 24;18(3):sfaf057. doi: 10.1093/ckj/sfaf057. eCollection 2025 Mar.
6
Successful outcome of a refractory IgA vasculitis nephritis in children treated with telitacicept.用泰吉华单抗治疗的儿童难治性IgA血管炎肾炎的成功结果
CEN Case Rep. 2025 Mar 1. doi: 10.1007/s13730-025-00983-6.
7
The road ahead: emerging therapies for primary IgA nephropathy.前方的道路:原发性IgA肾病的新兴疗法
Front Nephrol. 2025 Feb 4;5:1545329. doi: 10.3389/fneph.2025.1545329. eCollection 2025.
8
Energy metabolism in health and diseases.健康与疾病中的能量代谢。
Signal Transduct Target Ther. 2025 Feb 18;10(1):69. doi: 10.1038/s41392-025-02141-x.
9
What is new in the pathogenesis and treatment of IgA glomerulonephritis.IgA 肾小球肾炎发病机制与治疗方面的新进展有哪些。
World J Nephrol. 2024 Dec 25;13(4):98709. doi: 10.5527/wjn.v13.i4.98709.
10
The Latest Progress in the Application of Telitacicept in Autoimmune Diseases.泰它西普在自身免疫性疾病中的应用最新进展
Drug Des Devel Ther. 2024 Dec 7;18:5811-5825. doi: 10.2147/DDDT.S493923. eCollection 2024.